The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.

Abstract excerpt

A key component of personalized medicine is companion diagnostics that measure biomarkers, for example, protein expression, gene amplification or specific mutations. Most of the recent attention concerning molecular cancer diagnostics has been focused on the biomarkers of response to therapy, such as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in metastatic colorectal cancer, epidermal...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Apolipoprotein E4
• Share to Clinical Trials as Topic
• Share to Early Diagnosis